Sugi Predict

Sugi Predict / Compounds / Methylglyoxal

Methylglyoxal

Methylglyoxal

SCHEMBL2952275

CC(=O)C=O.NNC(=O)c1ccc(NN)cc1.NNC(=O)c1ccc(NN)cc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.50
▸ MPO P05164 2/20 0.50
▸ CYP3A4 P08684 2/20 0.50
▸ KDM5A P29375 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ GFER P55789 1/20 0.50
▸ PMP22 Q01453 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ CA1 P00915 2/20 0.49
▸ CA2 P00918 2/20 0.49
▸ ALDH1A1 P00352 5/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ LMNA P02545 2/20 0.48
▸ OGG1 O15527 1/20 0.48
▸ CA9 Q16790 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ ADORA3 P0DMS8 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2A6 P11509 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6469729 0.87 MPO (0.64) MAPTMPOCYP3A4KDM5ABLM
Methylglyoxal SCHEMBL5582423 0.85 TP53 (0.46) MAPTCA1CA2ALDH1A1KDM4E
SCHEMBL5924140 0.85 MAPT (0.46) MAPTMPOCYP3A4KDM5ABLM
Hydrochloric Acid SCHEMBL28169553 0.85 MPO (0.61) MAPTMPOCYP3A4KDM5ABLM
Phenylhydrazine SCHEMBL5581958 0.77 TDP1 (0.58) MAPTCYP3A4ALDH1A1KDM4EL3MBTL1
SCHEMBL343630 0.76 MPO (0.80) MAPTMPOCYP3A4KDM5ABLM
SCHEMBL2678949 0.76 MPO (0.80) MAPTMPOCYP3A4KDM5ABLM
SCHEMBL2924725 0.76 CACNA1B (0.65) MAPTMPOCYP3A4KDM5ABLM
SCHEMBL1105708 0.75 HDAC2 (0.59) MAPTMPOCYP3A4KDM5ABLM
SCHEMBL965061 0.75 MPO (0.59) MAPTMPOCYP3A4KDM5ABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1576093-A4 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS INC (US) 2009-07-08 — — EP claimed
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin DYNAMIS THERAPEUTICS, INC. 2007-03-22 — — US claimed
EP-1576093-A2 3-DEOXYGLUCOSONE AND SKIN Dynamis Therapeutics, Inc. (US) 2005-09-21 — — EP claimed
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) DYNAMIS THERAPEUTICS, INC. 2005-07-21 — — US claimed
US-20030219440-A1 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. 2003-11-27 — — US claimed
WO-2003089601-A2 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS, INC. (US) 2003-10-30 — — WO claimed
US-5661139-A FOR INHIBITING GLYCOSYLATION OF PROTEINS TO PREVENT DISCOLORATION OF THE TEETH ALTEON INC. (US) 1997-08-26 — — US claimed
WO-1996040622-A1 BIS-(2-ARYL)HYDRAZONES AS INHIBITORS OF THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS ALTEON INC. (US) 1996-12-19 — — WO claimed
US-20100310482-A1 3-Deoxyglucosone And Skin DYNAMIS THERAPEUTICS, INC. (US) 2010-12-09 — — US disclosed
US-7749503-B2 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. (US) 2010-07-06 — — US disclosed
US-7671019-B2 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) DYNAMIS THERAPEUTICS, INC. (US) 2010-03-02 — — US disclosed
US-7622117-B2 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. (US) 2009-11-24 — — US disclosed
EP-1576093-A4 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS INC (US) 2009-07-08 — — EP disclosed
US-20080292568-A1 3-Deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. (US) 2008-11-27 — — US disclosed
US-20030219440-A1 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS, INC. 2003-11-27 — — US disclosed
WO-2003089601-A2 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS, INC. (US) 2003-10-30 — — WO disclosed
EP-1175155-A1 METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF FOX CHASE CANCER CENTER (US) 2002-01-30 — — EP disclosed
WO-2000062626-A1 METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF FOX CHASE CANCER CENTER (US) 2000-10-26 — — WO disclosed
US-5661139-A FOR INHIBITING GLYCOSYLATION OF PROTEINS TO PREVENT DISCOLORATION OF THE TEETH ALTEON INC. (US) 1997-08-26 — — US disclosed
WO-1996040622-A1 BIS-(2-ARYL)HYDRAZONES AS INHIBITORS OF THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS ALTEON INC. (US) 1996-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070065443-A1 Fructoseamine 3 kinase and the formation of collagen and elastin FN3K, PDXK, COLGALT1 MAPT 677/4885MPO 2045/4885CYP3A4 4738/4885
US-20100310482-A1 3-Deoxyglucosone And Skin DPM1, G6PD, UGGT1 MAPT 3453/4885MPO 2095/4885CYP3A4 2484/4885
US-20080292568-A1 3-Deoxyglucosone and skin DPM1, G6PD, UGGT1 MAPT 3453/4885MPO 2095/4885CYP3A4 2484/4885
US-20030219440-A1 3-deoxyglucosone and skin DPM1, G6PD, UGGT1 MAPT 3453/4885MPO 2095/4885CYP3A4 2484/4885
US-20050159383-A1 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) AGER, GLA, GALE MAPT 2715/4885MPO 352/4885CYP3A4 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.